Investors. Word is out that Belviq is effective for individuals with obesity gene defect because it targets the GPR119 receptor / peptide YY ... Give Arena time, they're in a quiet period for a reason, otherwise they wouldn't be sitting quiet about today's patent granted! -SV
Ah yes, there's that reference to ASTHMA again in today's patent!!!! -SV
"Although a number of receptor classes exist in humans, by far the most abundant and therapeutically relevant is represented by the G protein-coupled receptor (GPCR) class. It is estimated that there are some 30,000-40,000 genes within the human genome, and of these, approximately 2% are estimated to code for GPCRs.
GPCRs represent an important area for the development of pharmaceutical products. Drugs active at GPCRs have therapeutic benefit across a broad spectrum of human diseases as diverse as pain, cognitive dysfunction, hypertension, peptic ulcers, rhinitis, and ASTHMA. " Ah yes, ASTHMA!!!
include bone-related conditions, metabolic disorders, angiogenesis-related conditions, ischemia-related conditions, convulsive disorders, malabsorptive disorders, cancers, and inflammatory disorders.
12, And specifically - WEIGHT LOSS! This patent is VERY IMPORTANT for Belviq along with future DIABETES work Arena is under-scoring! THIS PATENT IS A BIGGY! I wonder how many people will realize the impact and value this has? It's a BLOCK-BUSTER PATENT! That's right! It carries enormous intellectual property value for Arena! -SV ....Just wait until Big Pharma gets their eyes on this gem!!! Or have they already?